医药行业周报：AI为健康产业持续赋能

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1]. Core Insights - AI continues to empower the healthcare industry, with the integration of DeepSeek expected to accelerate its adoption [3]. - The trend of AI in drug development is gradually forming, reshaping traditional drug R&D processes [5]. - The external environment for CROs may change, with AI+CRO integration enhancing capabilities [7]. - Illumina's inclusion in the unreliable entity list by the Ministry of Commerce is accelerating the localization of the gene sequencing industry [9]. - Progress in CAR-T therapy technology is noteworthy, with universal CAR-T therapies beginning clinical trials [11]. - The market for diabetes and weight loss treatments is expanding, with significant innovations in NASH therapies [12]. Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 1.53 percentage points over the past week, with a growth of 2.71% [25]. - Over the past month, the industry also outperformed the CSI 300 index by 2.75 percentage points, achieving a growth of 6.51% [28]. - The medical services sub-sector showed the highest weekly and monthly growth rates of 6.51% and 15.03%, respectively [31]. 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) is 31.17, below the historical average of 33.13 [46]. - The industry has experienced a 5.17% decline over the past three months, underperforming the CSI 300 index by 2.68 percentage points [44]. 3. Recent Research Achievements - The research team has published several in-depth reports highlighting positive trends in the supply and demand sides of the pharmaceutical industry [50]. 4. Recent Industry Policies and News - The National Medical Insurance Administration has issued a list of key tasks for 2025, focusing on improving efficiency in the medical insurance sector [52]. - Recent news includes various drug approvals and clinical trial advancements from companies like Kangfang Biotech and Betta Pharmaceuticals [54]. 5. Key Companies and Profit Forecasts - The report recommends several companies based on their performance and market potential, including Xintai, Zhongsheng Pharmaceutical, and Kangxino [15].